Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate zanzalintinib showing potential to offset future revenue losses.

Investment analysts at TD Cowen began coverage on shares of CG Oncology (NASDAQ:CGON – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The ...

Immunotherapy represents a groundbreaking approach to combating various diseases by harnessing and enhancing the body’s ...

Greek-American actor John Stamos marked his nameday on January 7, with a post reflecting on his Greek heritage and the influential people in his family bearing the same first name. "Today I celebrate ...